May 8, 2018 / 11:19 AM / 5 months ago

BRIEF-Valeant Reports Q1 Loss Per Share $7.68

May 8 (Reuters) - Valeant Pharmaceuticals International Inc :

* VALEANT ANNOUNCES FIRST-QUARTER 2018 RESULTS AND RAISES REVENUE AND ADJUSTED EBITDA (NON-GAAP) GUIDANCE

* Q1 REVENUE $1.995 BILLION VERSUS I/B/E/S VIEW $1.94 BILLION

* Q1 LOSS PER SHARE $7.68

* Q1 EARNINGS PER SHARE VIEW $0.59 — THOMSON REUTERS I/B/E/S

* VALEANT - COMPANY’S NAME WILL CHANGE TO BAUSCH HEALTH COMPANIES INC. IN JULY 2018

* VALEANT SEES 2018 FULL-YEAR REVENUES IN RANGE OF $8.15 - $8.35 BILLION

* VALEANT - REPAID APPROXIMATELY $280 MILLION OF DEBT WITH CASH ON HAND IN Q1 OF 2018

* VALEANT SEES 2018 ADJUSTED EBITDA (NON-GAAP) IN RANGE OF $3.15 - $3.30 BILLION

* QTRLY ADJUSTED NET INCOME ATTRIBUTABLE TO VALEANT PHARMACEUTICALS INTERNATIONAL INC $312 MILLION

* VALEANT - GOODWILL IMPAIRMENT CHARGES OF $2.213 BILLION IN QUARTER RELATED TO SALIX AND ORTHO DERMATOLOGICS BUSINESSES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below